Month: July 2023

The FDA has authorized a mobile app called AspyreRx, developed by Better Therapeutics, as a treatment for type 2 diabetes. This regulatory decision creates a new class of therapies for the metabolic disorder. AspyreRx is a prescription digital therapeutic that digitizes cognitive behavioral therapy, which is already part of diabetes care. The app allows patients […]

Continue Reading

The U.S. Food and Drug Administration (FDA) has provided an update on various activities happening within the agency. One of the main focuses is the prevention of illicit xylazine from entering the United States. The FDA’s Center for Veterinary Medicine (CVM) is working in collaboration with other FDA offices and the Department of Health and […]

Continue Reading

Septerna Therapeutics has secured $150 million in Series B financing to support the development of its small molecule drug candidate for the treatment of hypoparathyroidism. The funding round was led by RA Capital Management and included participation from a range of investors, including Deep Track Capital, Goldman Sachs Asset Management, and Vertex Ventures HC, among […]

Continue Reading

UK-based immersive technology company FourPlus has secured funding from Innovate UK, the UK’s national innovation agency, to develop a mixed reality training platform for pharmaceutical companies and the healthcare sector. FourPlus already uses its immersive technology, including virtual reality experiences, in the life sciences sector for marketing, training, and workforce management. With a ₤1 million […]

Continue Reading

CellTrans, a small biotech company, has received the first FDA approval for a cell therapy for type 1 diabetes. The therapy, known as Lantidra, is intended for adults with type 1 diabetes who are unable to achieve their target blood glucose levels through regular insulin administration. Lantidra, which is made from pancreatic cells sourced from […]

Continue Reading

A targeted cancer therapy developed by AstraZeneca and Daiichi Sankyo has shown promising results in a Phase 3 study for advanced non-small cell lung cancer (NSCLC). The drug, called datopotamab deruxtecan, demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy. However, the companies also disclosed that an unspecified number of patient deaths occurred […]

Continue Reading

Johnson & Johnson (J&J) is making progress in developing a pill formulation to treat plaque psoriasis, a skin disorder that is currently treated with injectable biologic drugs. The company presented mid-stage data for its experimental drug JNJ-2113 at the World Congress of Dermatology meeting in Singapore. The study showed that a higher proportion of patients […]

Continue Reading

Lexington, Massachusetts-based biotech company Curis has received clearance from the FDA to resume a clinical trial that was placed on hold for over a year. The trial is testing the drug emavusertib, which is designed to block the enzyme IRAK4, involved in certain cancers and inflammatory diseases. The trial was put on hold after a […]

Continue Reading

The U.S. Food and Drug Administration (FDA) has released a summary of recent news and updates. First, the FDA issued a letter to health care providers recommending conservation strategies for non-sterile, single-use pneumatic tourniquet cuffs. The agency provided a list of best practices for cleaning and sterilization/disinfection of these devices and recommended the use of […]

Continue Reading